AZD3463 ALK/IGF1R Inhibitor: Mechanistic Evidence for Neuroblastoma Research

Executive Summary. AZD3463 is a novel, high-affinity ALK/IGF1R inhibitor developed by APExBIO for preclinical and translational oncology research (product page). It selectively blocks ALK and IGF1R kinase activity (Ki = 0.75 nM), suppressing the PI3K/AKT/mTOR signaling pathway essential for neuroblastoma cell survival and proliferation. AZD3463 is effective against both wild-type and activating ALK mutations (F1174L, D1091N), induces apoptosis and autophagy in vitro and in vivo, and demonstrates synergy with standard chemotherapeutics such as doxorubicin and temozolomide. The compound is insoluble in water/ethanol but highly soluble in DMSO (≥11.22 mg/mL), facilitating flexible experimental design. These properties position AZD3463 as a benchmark tool for ALK-driven cancer research and resistance management (Labrèche et al. 2021).

Biological Rationale

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase highly expressed in neurons and frequently upregulated in neuroblastoma tumors. ALK activation triggers the PI3K/AKT/mTOR pathway, promoting tumor cell survival, proliferation, and resistance to apoptosis (Labrèche et al. 2021). Mutations such as F1174L and D1091N confer constitutive ALK activity, contributing to aggressive disease and poor prognosis. IGF1R signaling also converges on the PI3K/AKT axis, creating an oncogenic network. Inhibition of these pathways has demonstrated efficacy in reducing tumor growth and overcoming drug resistance. AZD3463 targets both ALK and IGF1R, making it suitable for research into these molecular dependencies.

Mechanism of Action of AZD3463 ALK/IGF1R inhibitor

AZD3463 is a small-molecule kinase inhibitor with a molecular weight of 448.95 Da and the formula C₂₄H₂₅ClN₆O (APExBIO). It binds ALK and IGF1R with high affinity (Ki = 0.75 nM), competitively inhibiting ATP binding. This blockade suppresses downstream PI3K/AKT/mTOR signaling, leading to cell cycle arrest, apoptosis, and autophagy in neuroblastoma models. In preclinical studies, AZD3463 induces dose-dependent inhibition of cell growth (5–50 μM) and is effective against both wild-type and mutant ALK forms. The compound also acts synergistically with chemotherapeutic agents, enhancing cytotoxicity and promoting cell death via multiple mechanisms (Labrèche et al. 2021).

Evidence & Benchmarks

• AZD3463 inhibits ALK kinase activity with Ki = 0.75 nM, providing high selectivity and potency (APExBIO).
• Suppresses proliferation of neuroblastoma cell lines harboring wild-type or mutant ALK (F1174L, D1091N) in vitro at 5–50 μM in serum-containing media (Labrèche et al. 2021).
• Induces apoptosis and autophagy, as shown by increased caspase activation and LC3-II accumulation in treated neuroblastoma cells (Labrèche et al. 2021).
• Shows synergistic cytotoxicity when combined with doxorubicin or temozolomide in cell viability and colony formation assays (APExBIO).
• In vivo, 15 mg/kg AZD3463 (i.p., daily ×2) significantly reduces tumor burden in orthotopic neuroblastoma xenograft mice with both wild-type and mutant ALK (Labrèche et al. 2021).

For a comparative view on the unique mechanistic features and strategic recommendations for translational research, see Redefining ALK-Driven Cancer Research—the present article updates and expands on resistance mechanisms and combination therapy context.

For a detailed systems biology perspective on pathway cross-talk and resistance, refer to AZD3463 ALK/IGF1R Inhibitor: Systems Biology Insights; this article provides new experimental parameters and application boundaries.

Applications, Limits & Misconceptions

AZD3463 is primarily used for research into ALK-driven neuroblastoma and other malignancies with aberrant ALK/IGF1R signaling. It is valuable for modeling resistance to first-generation ALK inhibitors (e.g., crizotinib), studying PI3K/AKT/mTOR pathway inhibition, and evaluating combination regimens with DNA-damaging agents.

Common Pitfalls or Misconceptions

• Inactive against ALK-negative cell lines: AZD3463 shows minimal cytotoxicity in tumor models lacking ALK expression or activation.
• Not water- or ethanol-soluble: Incorrect solvent use can result in precipitation and loss of potency; DMSO is required for stock solutions.
• Not validated for clinical use: AZD3463 is for laboratory research only and is not approved for human therapy.
• Long-term solution instability: AZD3463 solutions in DMSO should not be stored long-term (>several months) due to potential degradation.
• Limited efficacy in tumors with bypass pathway activation: Tumors with alternative survival mechanisms may not respond to ALK/IGF1R blockade alone.

Workflow Integration & Parameters

AZD3463 (A8620) is supplied by APExBIO as a solid compound. The recommended preparation is dissolution in DMSO at ≥11.22 mg/mL, with gentle warming or sonication to enhance solubility. Stocks should be aliquoted and stored at −20°C; avoid repeated freeze-thaw cycles. For cell-based assays, dilute DMSO stocks in culture media to final concentrations (5–50 μM); maintain DMSO below 0.1% v/v. For animal studies, dissolve in sterile DMSO and dilute into compatible carriers before intraperitoneal injection. Typical in vivo dose is 15 mg/kg/day for 2 days in mouse xenograft models (APExBIO). Long-term solution storage is not recommended.

For mechanistic precision, see AZD3463 ALK/IGF1R Inhibitor: Mechanistic Precision, which our article extends by providing new solution handling and combination therapy details.

Conclusion & Outlook

AZD3463 ALK/IGF1R inhibitor is a benchmark tool for ALK-driven cancer research, enabling studies of resistance, pathway inhibition, and combination regimens. By targeting both ALK and IGF1R, it offers a means to dissect oncogenic signaling, induce apoptosis/autophagy, and model the impact of PI3K/AKT/mTOR axis blockade. Future research will further clarify its translational potential and optimal use in complex tumor contexts. For product details and ordering, visit the AZD3463 product page.